Naltrexone Implant Knowledge Library

Explore the latest scientific studies and clinical research on Naltrexone Implants. Click any title to read the full PubMed article.

• An Analysis of Treatment Preferences of Patients With Opioid Use Disorders: Findings From A Tertiary Drug Dependence Treatment Center in India
  September 16, 2026 by Shalini Singh
  CONCLUSION: There was a greater preference for oral opioid agonist medication over all other formulations. A wider availability of medications for opioid agonist maintenance treatment could improve treatment-seeking rates. Further research on […]
• Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies
  August 27, 2026 by Fani-Niki Varra
  Obesity is a multifactorial condition that profoundly affects female reproductive health through endocrine, metabolic, and inflammatory mechanisms that disrupt the hypothalamic-pituitary-gonadal (HPG) axis. Women with obesity frequently develop menstrual irregularities, anovulation, amenorrhea, […]
• Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta-analysis and meta-regression
  June 12, 2026 by Emmert Roberts
  CONCLUSIONS: Very low certainty evidence suggests that, among people with opioid use disorder who have undergone withdrawal and wish to remain abstinent, a substantial percentage are willing to initiate naltrexone with marked […]
• A Membrane-Centric Plasma Lipidomic Signature of Response to Long-Acting Naltrexone in Alcohol Use Disorder
  May 12, 2026 by Liyao Huang
  Long-acting naltrexone is a first-line pharmacotherapy for alcohol use disorder (AUD), but clinical response is heterogeneous and the underlying biology remains incompletely understood. In a randomised, double-blind, placebo-controlled trial of naltrexone implants […]
• A Long-acting Naltrexone Implant (iSTEP-N) for Opioid Use Disorder: First-in-Human Phase I Trial
  January 26, 2026 by Steven M Cohen
  CONCLUSIONS: At the 9.6 g dose, iSTEP-N provided sustained therapeutic naltrexone exposure for 12 weeks with a favorable safety profile, while releasing less than one-fourth of its drug content. Further studies will […]
• Differential Antipyretic Effects of Toll-Like Receptor 4 Signal Inhibitors in Male Rats
  December 10, 2025 by Tuğçe Nomenoğlu
  CONCLUSION: Data show that TLR4 signal inhibitors have differential antipyretic activity on fever suggesting that some alternative or complementary mechanisms might be operational for LPS-induced fever. Data also suggest that TLR4 signal […]
• Treatment of compulsive sexual behavior disorder (CSBD) with a naltrexone implant: A case report
  September 10, 2025 by Liu Liu
  No abstract
• Fentanyl-blocking effects of extended-release naltrexone in humans: Three case reports
  September 5, 2025 by Colin Brewer
  Despite the contribution of the µ-agonist fentanyl to the United States's opiate overdose epidemic, no human studies specifically address the ability of extended-release preparations of the opiate antagonist naltrexone (NTX) to block […]
• Managing Burning Mouth Syndrome: Current and Future Directions
  August 15, 2025 by Linda Sangalli
  Burning mouth syndrome (BMS) is a chronic pain condition characterized by a persistent burning sensation in the oral mucosa in the absence of visible clinical signs. Its management remains a significant clinical […]
• Comparison of Naltrexone Implant and Oral Buprenorphine Naloxone in The Treatment of Opioid Use Disorder: A Retrospective Cohort Study
  June 30, 2025 by Oğuz Peker
  CONCLUSION: The findings of our study show that XR-NTX may be more effective than BN-NX in preventing relapse in OUD. In addition, it was concluded that probation, age of onset of substance […]
• Mortality during and following treatment with extended-release naltrexone based on data from two clinical trials
  June 21, 2025 by L Gjersing
  AIMS: To examine mortality during and in the first year following extended-release naltrexone (XR-NTX) treatment in patients with opioid use disorder (OUD).
• Alternating self-administration sessions of cocaine and heroin impact drug-related motivation and vocalisations in rats
  June 9, 2025 by Kristian Adamatzky
  CONCLUSIONS: Distinct patterns emerged in motivation and USVs between cocaine and heroin self-administration. Notably, USV frequency did not consistently align with motivation, especially when drug dosage changed. Future research may clarify this […]
• Sustained-release naltrexone for opioid dependence
  May 9, 2025 by Hege Kornør
  BACKGROUND: Opioid dependence is a severe and often lifelong disorder with a high risk of overdose and premature death, as well as severe psychosocial difficulties. Sustained-release naltrexone is a treatment option that […]
• Evaluating the antagonist effect of naltrexone implant via opioid challenge tests with escalating doses of hydromorphone injection in former heroin dependent patients
  February 14, 2025 by Wei Qu
  Opioid dependence is a serious, life-threatening condition with severe social impacts. Naltrexone (NTX) can weaken the effect of opioids and effectively reduce opioid self-administration, discrimination, and opioid-induced subjective effects, and the oral […]
• Memory enhancement by unconditioned and conditioned heroin withdrawal: Role of corticotropin-releasing factor in the central amygdala
  February 9, 2025 by Nana Baidoo
  To test the hypothesis that unconditioned and conditioned opioid withdrawal enhance memory consolidation through shared neurobiological mechanisms, the current study focused on the central amygdala (CeA) and local corticotropin-releasing factor (CRF) neurotransmission. […]
• Extended-release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review
  January 31, 2025 by Amelia Woods
  CONCLUSIONS: There is no clear evidence for the effectiveness of extended release naltrexone and buprenorphine among individuals in the criminal justice system compared with shorter acting formulations. But there is growing evidence […]
• Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review
  January 6, 2025 by Janelle Duah
  CONCLUSION: Clinically significant and meaningful weight loss is achievable with pharmacotherapy to help enhance fertility in women of reproductive age who are overweight or obese. Current research supports the use of weight […]
• Ultra-Long-Term Delivery of Hydrophilic Drugs Using Injectable In Situ Cross-Linked Depots
  September 10, 2024 by Sohyung Lee
  Achieving ultra-long-term release of hydrophilic drugs over several months remains a significant challenge for existing long-acting injectables (LAIs). Existing platforms, such as in situ forming implants (ISFI), exhibit high burst release due […]
• Loss of Consciousness After Naltrexone Implantation: A Case Report
  September 3, 2024 by Oğuzhan Doğan
  Naltrexone is an μ opioid receptor antagonist that is used in alcohol and opiate use disorder. Naltrexone does not constitute tolerance and dependence, and cessation of the drug does not cause withdrawal […]
• Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl-induced respiratory depression at 3 months-A pilot study in male canines
  August 9, 2024 by Robert L Joyner
  The aim of this study is to determine if extended-release, bioabsorbable, subcutaneous naltrexone (NTX) implants can mitigate respiratory depression after an intravenous injection (IV) of fentanyl. Six different BIOabsorbable Polymeric Implant Naltrexone […]